Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1, EVOLVE‐2, and REGAIN Studies

• Published in: Headache Vol. 60; no. 1; pp. 110 - 123
• Main Authors: Oakes, Tina M., Kovacs, Richard, Rosen, Noah, Doty, Erin, Kemmer, Phebe, Aurora, Sheena K., Camporeale, Angelo
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.01.2020
• Subjects: Adult; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Blood pressure; Blood Pressure - drug effects; Calcitonin; Calcitonin Gene-Related Peptide - drug effects; calcitonin gene‐related peptide; Cardiovascular Diseases - chemically induced; cardiovascular risks; Chronic Disease; Confidence intervals; Covariance; Double-blind studies; Drug therapy; Echocardiography; EKG; Electrocardiography; Electrocardiography - drug effects; Embolism; Embolisms; Female; galcanezumab; Headache; Health risks; Heart attacks; Heart Rate - drug effects; Humans; hypertension; Ischemia; Male; Microvasculature; Middle Aged; Migraine; Migraine Disorders - prevention & control; Monoclonal antibodies; Myocardial infarction; Patients; Randomization; Thromboembolism; Thrombosis; Transient ischemic attack; Treatment Outcome; calcitonin gene-related peptide; cardiovascular risks; migraine; hypertension; galcanezumab; ischemia

Objective Blood pressure (BP), pulse, electrocardiogram (ECG), and clinical cardiovascular (CV) outcomes in patients with episodic or chronic migraine treated for up to 6 months with galcanezumab compared to placebo were evaluated. Background Calcitonin gene‐related peptide, a potent microvascular v...